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Nonmutagenic Carcinogens Induce
Intrachromosomal Recombination in
Dividing Yeast Cells
by Robert H. Schiesti
A large number of animal and human carcinogens without apparent genotoxic activity exist
(nonmutagenic carcinogens) that are difficult or impossible to detect with the currently used
short-term tests. Because of the association of carcinogenesis with genome rearrangement, a
system selecting for intrachromosomal recombination (DEL recombination) that results in
genome rearrangement has been constructed in the yeast Saccharomyces cerevisiae. Because
DEL recombination is under different genetic control than interchromosomal recombination
and meiotic recombination, it is probably due to a different mechanism. It has been found that
DEL recombination is readily inducible by 10 mutagenic carcinogens and 17 nonmutagenic car-
cinogens that are not detectable (false negatives) with the Ames assay. In addition, three out of
four mutagens that do not cause cancer (false positives in the Ames assay) do not induce DEL
recombination. DEL recombination is inducible by UV only in dividing cells but not in cells syn-
chronized in the G, or G2 phase ofthe cell cycle. Interchromosomal recombination, on the other
hand, is inducible in GI but not in G2. The nonmutagenic carcinogens induce DEL recombina-
tion only in actively growing cells, which may give some indication as to their mechanism.
Further characterization of the mechanism involved in induction of DEL recombination may
contribute to the understanding ofthe biological activity ofnonmutagenic carcinogens.
Introduction
It has been estimated that about 70-90% of new
cases of cancer are linked to environmental carcino-
gens. A majority of these new cases might be pre-
ventable if the main risk and antirisk factors could be
identified (1). At present, the regulation of environ-
mental carcinogens is primarily based on long-term
animal bioassays. Long-term animal bioassays are
very costly and take 2-4 years to perform. Short-term
bioassays, on the other hand, are very inexpensive by
comparison, and they may produce results within 1
week or sooner. Therefore, prescreening chemicals
with a short-term test would be highly desirable, espe-
cially ifit would be possible to predict the carcinogenic
potential of any given substance with a reasonably
high level of accuracy (2). This would be especially
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important for industries producing pharmaceuticals,
cosmetics, and food additives, because potential car-
cinogenic effects could be identified at an early stage in
the development ofa product.
A large amount of data establishes that animal and
human carcinogens exist that do not exhibit any appar-
ent genotoxic activity. These carcinogens are difficult
or impossible to detect by the currently used short-
term tests (3). The Ames or Salmonella assay, which is
based on the induction of mutations in Salmonella
typhimurium (4), and which is currently the most
widely used short-term test, has recently been report-
ed to detect only 56% of carcinogens (5). There are
more than 60,000 synthetic chemicals in commercial
use. New chemicals are introduced at a rate of 1,000
per year, some of which may pose a significant health
risk to humans. The overwhelming majority of chemi-
cals in our environment have not been tested for their
carcinogenic activity in long-term studies. More chemi-
cals have been tested with short-term tests, but there
is considerable concern that there may be a large num-
ber of carcinogens in our environment that cannot be
detected by conventional short-term tests. Long-term
tests are not inherently suitable for solving this prob-
lem in the near future. On the other hand, short-termR. H. SCHIESTL
studies, iftheir sensitivity could be increased, might be
used to solve this problem.
Because animal carcinogens exist that do not exhibit
any apparent genotoxic activity, the scientific commu-
nity has tried to explain the carcinogenic effect of
these chemicals in many different epigenetic ways (6).
Also, because models for carcinogenesis of nongeno-
toxic carcinogens are largely missing, a significant reg-
ulatory dilemma exists in assessing their risk to
humans (7).
Another problem with long-term bioassays that use
whole vertebrate animals is the growing public con-
cern about the suffering of laboratory animals. The
pressure from animal-welfare advocates, the high cost,
and the delays imposed by animal testing for bringing
chemicals to the marketplace are pushing regulatory
agencies to decrease the number of animal tests
required. The ultimate solution to this dilemma would
be in vitro tests that can partly replace or limit the
number ofthe whole-animal tests. Such an in vitro test
is presented in this paper.
The first study that established an association
between cancer-causing activity and the mutagenic
activity of many different agents was carried out by
Ames and co-workers (4). In this study, a 90% correla-
tion between carcinogenicity and mutagenicity was
reported for 300 chemicals. Since then, the Ames assay
or Salmonella assay, based on the induction of muta-
tions in Salmonella typhimurium, has been widely
used and is currently the best characterized short-term
test. However, in recent reports, only about 56% ofthe
carcinogens tested have been reported to be detectable
with the Salmonella assay (5). In an international col-
laborative study with 42 coded chemicals evaluating 30
different short-term tests in more than 50 different lab-
oratories (8), it was found that the best assays identi-
fied only 70% of the chemicals correctly and that two-
thirds ofall tests identified only between 40 and 60% of
the chemicals correctly. Sixty laboratories have taken
part in a second similar study with eight carcinogens
and two noncarcinogens (9). The overall performance
was between 40 and 60% ofthe chemicals classified cor-
rectly. Another study (10) compared 4 in vitro tests
with 73 chemicals which were sufficiently tested for
their carcinogenic activity by the National Toxicology
Program (NTP). These assays identified between 60
and 62% ofthe chemicals correctly. Furthermore, it has
recently been reported by Ashby and Tennant (5) that
the Salmonella assay identified only 63% of 301 chemi-
cals correctly. These chemicals were sufficiently tested
fortheir carcinogenic activity in long-term bioassays by
the U.S. NTP. Furthermore, 65% ofall chemicals were
correctly identified on the basis of structural alerts.
These results led Ashby and Tennant (5) to the conclu-
sion: "Structural alerts and mutagenicity to Salmonella
are useful but nondefinitive indicators ofthe overt car-
cinogens in the database, and the activity of the
remaining (putative nongenotoxic) carcinogens is not
predictable using current techniques.
Materials and Methods
Strains and Media
The diploid strain RS112 (MATa/a ura3-521ura3-52
leu2-3,11211eu2-A98 trp5-271TRP5 arg4-31ARG4 ade2-
401ade2-101 ilvl-921ILVi HIS3::pRS61his3-A200 LYS2/
lys2-801) (11) was used and contains the deletion
(DEL) system on one homolog (HIS3::pRS6) and a
deletion of the entire open-reading frame of HIS3 on
the other homolog (his3-A200, 12). YPAD (yeast
extract 1%, peptone 2%, dextrose 2%, adenine sulfate
30mg/L, agar 2% in distilled water) and synthetic mini-
mal media (SC) were prepared as described previously
(13).
Determination ofthe DEL
Recombination Rates and
Interchromosomal Recombination
Frequencies
Plasmid pRS6 containing an internal fragment ofthe
HIS3 gene has been integrated at the genomic HIS3
site. This resulted in two copies of the his3 gene, one
with a terminal deletion of the 3' end and the other
with a terminal deletion at the 5' end [Fig. 1 (14)].
In cells of strain RS112 carrying the genomic inte-
gration of the plasmid pRS6, about 99% of HIS3+
recombinants lose the LEU2 gene [Fig. 1 (14)]. There-
fore, the cultures used to select for HIS3+ recombi-
nants were pregrown on medium lacking leucine, and
after treatment they were plated onto medium lacking
histidine. Thus, growth and accumulation of recombi-
nants does not occur in the preculture, and therefore
the HIS3+ frequency is a measure ofthe recombination
rate which results in high reproducibility of sponta-
neous rates. Strain RS112 is also heteroallelic for ade2-
40 and ade2-101 so that interchromosomal recombina-
tion (ICR) between homologs can be measured.
The influence of various agents on the frequency of
deletions and interchromosomal recombination was
determined as described (15). Single colonies were
picked from YPAD medium and were inoculated into
5-25 mL of SC-LEU medium and grown for 24 hr at
30°C under constant shaking. Cells were counted, and
the cell density was adjusted to 2 x 106 cells/mL in
fresh SC-LEU medium. The medium containing the
cells was distributed in aliquots of5 mL each in dispos-
able 15 mL tubes. The agent to be tested was added,
the tubes sealed, and the cells were incubated for 17 hr
at 30°C under constant shaking. Cells were pelleted in
a clinical table-top centrifuge. The cells for 4-nitro-
quinoline-N-oxide (NQO), ethylmethanesulfonate (EMS),
and methylmethanesulfonate (MMS) treatment were
washed once with a 5% solution of sodium thiosulfate
to inactivate the agent and a second time with sterile
distilled water. For all other chemicals, the cells were
washed twice with sterile, distilled water. Thereafter
cells were resuspended in 0.5-1 mL of sterile, distilled
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FIGURE 1. Plasmid pRS6, which contains an internal fragment ofthe
HIS3 gene, was cut within the internal his3 fragment and inte-
grated into the genome at the HIS3 locus (a). This creates a dupli-
cation of the his3 gene in which one allele is deleted for its 3' end
and the other for its 5' end (b). The two alleles share about 400
basepairs of homology and thus can recombine with each other to
revert to the HISS+ allele. As shown previously, HISS+ recombi-
nants do not arise by plasmid excision or by unequal sister chro-
matid exchange (14). In these studies the frequency of plasmid
excision was determined by cloning a yeast origin of replication
sequence onto the integrating plasmid. Excised plasmids could be
recovered but were found 100 times less frequently than HIS+ for-
mation, suggesting that plasmid excision does not occur in the
majority of recombinants. Reciprocal products expected to result
from sister chromatid exchange were analyzed by Southern blot-
ting. The pattern characteristic for sister chromatid exchange was
not found in any of25 events examined. Thus, as a likely alterna-
tive mechanism, it is suggested that conversion between sister
chromatids (c) results in deletion ofthe integrated plasmid on one
chromatid (d). After segregation of the two chromatids, the HIS+
recombinant should show a HIS+ leu-phenotype, which is found in
99% of all HIS+ recombinants. As a possible model, it is proposed
that a double-strand break initiates the recombination event and
is then extended by an exonuclease to a gap. This gap is repaired
by gene conversion with the sister chromatid acting as donor (14).
water, transferred to a glass tube, and sonicated to dis-
perse any clumps. Cells were counted and appropriate
numbers were plated onto SC medium to determine
the number of survivors, onto SC-HIS medium to
score for DEL events, and onto SC-ADE medium to
determine the frequency of ICR events. The cells did
not contain any clumps of tetrads. Colonies were
counted after 2-3 days of incubation at 30°C. All data
given reflect the total number ofrecombination events
per number of cells capable of forming colonies (sur-
vivors) on nonselective medium.
Data derived from less than five colonies were not
included. A minimum increase of two-fold over the
spontaneous frequency in a dose-dependent manner
was regarded as evidence for inducibility. Each experi-
ment was repeated at least three times, and the results
obtained were highly reproducible. Two plates were
used for each system and each concentration. Details
on irradiation of cells and chemicals used can be found
in Table 1.
Results and Discussion
There is evidence in the current literature that sub-
stantial genome rearrangements are associated with
cancer (16-22). Deletions have been implicated in car-
cinogenesis caused by mutations in recessive onco-
genes such as retinoblastoma or colon cancer (23-24).
Leukemia may be caused by translocations (25).
Because of the association of genome rearrangement
with cancer, a system selecting for intrachromosomal
recombination that results in genome rearrangement
has been constructed in the yeast Saccharomyces cere-
visiae [Fig. 1 (14)]. A plasmid with an internal frag-
ment of the HIS3 gene has been integrated at the
HIS3 locus, yielding an integrative disruption of the
HIS3 gene. This resulted in two copies of the HIS3
gene, each having one terminal deletion. This construct
reverts to HIS3+ by recombination of the two his3
deletion alleles. This recombination event deletes 6 kb
ofDNA that comprise the entire integrated plasmid and
has therefore been termed a DEL event [Fig. 1 (15)].
Because of the involvement of deletions in carcino-
genesis, the inducibility of DEL recombination with
carcinogens has been studied. Carcinogens that are
positive in the Salmonella assay (mutagenic carcino-
gens) as well as carcinogens that are negative in the
Salmonella assay (nonmutagenic carcinogens) turned
out positive with the DEL assay (15,26,27). The yeast
strain RS112, containing a duplication of the HIS3
gene (each carrying different terminal deletions) was
used to determine the effects of different carcinogens
and other agents on intrachromosomal recombination
between the two his3- alleles (DEL recombination). In
addition, strain RS112 contained a system to select for
ICR between two homologous chromosomes. Carcino-
gens that are detectable with the Salmonella assay,
namely, UV and yirradiation, MMS, EMS, NQO, nitro-
gen mustard, epichlorohydrine, aflatoxin B1, ethylene
dibromide, and dimethylhydrazine, induced DEL as
well as the ICR frequencies (Table 1).
Carcinogens that are not detectable with the Salmo-
nella assay, namely, formaldehyde, safrole, eugenol,
ethionine, urethane, auramine, methylene chloride,
b
c
d
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Table 1. Inducibility ofintrachromosomal (DEL) and interchromosomal recombination (ICR) by different agents.
Response in Response in Response in
Agent Carcinogen Salmonella assay DEL ICR Reference
UVirradiation + + + + (27)
,y-Ray exposure + + + + (27)
MMS + + + + (15,27)
EMS + + + + (15,27)
NQO + + + + (15,27)
Nitrogen mustard + + + + (15,27)
Epichlorohydrin + + + + (15,27)
Aflatoxin B1 + + + + (15,27)
Ethylene dibromide + + + + (15,27)
Dimethylhydrazine + + + + (15,27)
Formaldehyde + - + + (15,27)
Safrole + - + +l- (15,26,27)
Eugenol + - + + (26)
Methyleugenol ? - + + (26)
Ethionine + - + - (15,27)
Urethane + - + - (15,27)
Auramine 0 + - + - (15,27)
Methylene chloride + - + - (15,27)
Carbon tetrachloride + - + - (15,27)
Cadmium chloride + - + - (15,27)
Cadmium sulfate + - + - (15,27)
Aniline + - + - (15,27)
3-Amino-1,2,4-triazole + - + - (15,27)
Acetamide + - + - (15,27)
Thioacetamide + - + - (15,27)
Thiourea + - + + (15,27)
DDE + - + + (15,27)
Ethylenethiourea + - + + (15,27)
Peroxisome proliferators + - - - (28)
Diethylstilbestrol + - - - (27)
Mezerein + - - - (27)
TPA + - - - (27)
Methionine - - - - (15,27)
Hydroxylamine HCl - - - + (27)
Sodium azide - + - + (27)
5-Bromouracil - + - (27)
2-Aminopurine - + + + (27)
Ethidium bromide ? + + + (27)
4-Aminoantipyrine ? - + + (27)
Abbreviations: MMS; methyl methanesulfonate; EMS, ethyl methanesulfonate; NQO, 4-nitroquinoline-N-oxide; dimethylhydrazine, sym-
dimethylhydrazine dihydrochloride; DDE, 2,2-bis(chlorophenyl)-1,1-dichloroethylene; peroxisome proliferators, Wy-14,643, methyl clofenopate,
nafenopin, ciprofibrate, BR931 and clofibrate were used; ?, equivocal or inconclusive carcinogenicity data.
carbon tetrachloride, cadmium chloride, cadmium sul-
fate, aniline, 3-aminotriazole, acetamide, thioacetamide,
thiourea, DDE, and ethylenethiourea, were all positive
with the DEL assay, but most of them did not induce
ICR (Table 1). Mutagens that do not show any signifi-
cant carcinogenic activity (false positives in the
Salmonella assay), namely, sodium azide and bro-
mouracil, did not induce DEL recombination but sodi-
um azide induced ICR. On the otherhand, aminopurine
and ethidium bromide induce both the DEL recombi-
nation and ICR.
It may not be surprising that highly tissue-specific
carcinogens, carcinogens that may act via hormone
imbalance, or tumor promotors would be negative with
the yeast system. For instance, peroxisome prolifera-
tors, which are liver carcinogens, diethylstilbestrol,
tetradecanoyl-13-phorbol acetate and mezerein are
negative with the standard DEL assay. Even though
six peroxisome proliferators were used (28), they were
included as one item in the calculation below and in
Table 1 because they represent a highly specific group
ofcarcinogens that may act in very similar ways.
The data show that 10 mutagenic carcinogens and 17
carcinogens that are not detectable with the Salmo-
nella assay induced the DEL assay, whereas four car-
cinogens that are negative with the Salmonella assay
were also negative with the DEL assay. The amino
acid methionine as well as two noncarcinogenic muta-
gens (sodium azide, 5-bromouracil) did not induce the
DEL assay, whereas the noncarcinogenic mutagen
aminopurine induced the DEL system and is therefore
a false positive. Thus, in 36 agents there were four
false negatives out of31 carcinogens, which results in a
sensitivity of0.87, and 1 false positive out of 5 noncar-
cinogens, which results in a specificity of 0.8 and in an
overall accuracy of 0.86 as defined in DeSerres and
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Ashby (8). This means that 86% of the chemicals were
identified correctly. Two-thirds ofthese agents (24 out
of 36) have been chosen because they are false nega-
tives or false positives in the Salmonella assay, and
thus the Salmonella assay only identified 33% ofthese
agents correctly. This seems tojustify the need for fur-
ther testing to determine the usefulness of the DEL
system as a short-term test.
In an international collaborative study that used
coded chemicals to evaluate 30 different short-term
assays in more than 50 different laboratories (8), the
carcinogens auramine, safrole, urethane, ethionine,
ethylenethiourea, and 3-aminotriazole gave very poor
inducibilities with all short-term tests. All ofthese car-
cinogens were correctly identified by the DEL assay.
When the two recombination systems DEL and ICR
were compared in their performance in detecting car-
cinogens, it was noticed that the mutagenic carcino-
gens induced both systems well. The nonmutagenic
carcinogens, on the other hand, induced DEL recombi-
nation much better than ICR. Also, the noncarcino-
gens hydroxylamine and sodium azide were false posi-
tives with the ICR system. Further similarity between
carcinogenesis and DEL recombination include that
nonmutagenic carcinogens may show a threshold in
their dose-response curve, which is not usually seen
with mutagenic carcinogens (29). Similarly, the nonmu-
tagenic carcinogens formaldehyde, auramine, safrole,
carbon tetrachloride, aniline, 3-aminotriazole, acetamide,
ethylene thiourea, urethane, and thioacetamide
showed a threshold for DEL induction, whereas the
mutagenic carcinogens did not show any threshold
(15).
Characterization of the mechanism involved in the
induction ofDEL recombination may contribute to the
understanding of the biological activity of nonmuta-
genic carcinogens because induced DEL recombination
is the only genotoxic effect some ofthese agents show.
DEL is under different genetic control from ICR and
meiotic recombination. Mutations in the DNA repair
genes RAD1, RADi0, and RAD52 each lower the fre-
quency ofDEL recombination about 4-fold (11,30). The
RAD52 gene product is involved in double-strand
break repair, in ICR and in meiotic recombination (31).
The RAD1 and RAD10 gene products are involved in
excision repair and have been shown to have no effect
on interchromosomal recombination or meiotic recom-
bination. It has further been shown that the radi and
rad52 mutations act synergistically and reduce DEL
recombination to a level far below the effect of each
single mutant, suggesting that the radi and rad52
genes work in different recombination pathways (11).
These data suggest that the mechanism of DEL
recombination differs from that of interchromosomal
recombination and meiotic recombination. Further-
more, DEL recombination is UV inducible in the radi
mutant but not in the rad52 mutant (Schiestl, unpub-
lished results). This indicates that the RAD52 pathway
is responsible for the induced recombination. The spon-
taneous rate is much reduced in the radl mutant.
However, induced recombination levels in the radi
mutant with UV, EMS, and MMS almost reach wild-
type levels so that the radl mutant is more sensitive to
detect these agents, especially at lower doses.
Preliminary studies (Schiestl, unpublished observa-
tions) defining the phase ofthe cell cycle in which DEL
recombination is inducible have shown that DEL
recombination is not inducible in G1 after UV irradia-
tion, whereas ICR is highly UV inducible in GI. DEL
as well as ICR are not UV inducible in cells synchro-
nized in G2, whereas both are highly UV inducible in
logarithmically growing cells. That ICR is inducible in
G1 but not in G2 has also been previously shown (32).
Thus, DEL recombination is UV inducible only in
actively growing cells, whereas ICR is in addition
highly inducible in G1. y-Rays and MMS induce DEL
recombination in logarithmically growing and in G2-
arrested cells, but less in G1-arrested cells. It has also
been shown that the nomutagenic carcinogens induced
DEL nonmutagenic recombination only in logarithmi-
cally growing cells but not in stationary cells (26,
Schiestl, unpublished observation).
DEL recombination may cycle in its sensitivity for
induction during the cell cycle and may be most sensi-
tive in the S and G2 phases, whereas ICR is most sensi-
tive in G1. Therefore, DEL recombination may be
inducible by agents that damage DNA directly or indi-
rectly in the S phase. For instance, they may interfere
with DNA replication or with DNA replication
enzymes or with other DNA metabolizing or DNA
repair activities. The damage they cause could be
repaired in the S or G2 phase (by sister chromatid
recombination) before cell division and therefore they
may not induce ICR, which is not inducible in this
phase. It is well documented that there is a checkpoint
in the G2 phase ofthe cell cycle, which is only released
when the cellular DNA is intact (33,34). That DEL
recombination is inducible by the nonmutagenic car-
cinogens exclusively in proliferating cells may repre-
sent another similarity between DEL recombination
and carcinogenesis because cell proliferation also
seems to be important for carcinogenesis.
Carcinogenesis is a multistage process; multiple
genetic events are necessary for neoplastic transfor-
mation ofa normal cell (35). For instance, a mutation of
one allele of a tumor-suppressor gene may predispose
an individual to cancer but loss of heterozygosity
(LOH) of the normal allele has to occur for expression
of the transformed phenotype (23). LOH may be
caused by deletion of the second allele. Provided that
DEL events in fact are recombination events between
sister chromatids, such events usually do not induce
point mutations or ICR and are thus genetically silent.
This might explain the nonmutagenic character of car-
cinogens that only induce DEL. Sister chromatid
recombination events may give rise to recombination
events between repeated elements, yielding genome
rearrangements and bringing proto-oncogenes (36)
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into proximity with promoter or enhancer sequences.
Sister chromatid recombination can also lead to gene
amplification, which may also be involved in carcino-
genesis (37).
If, after further evaluation, results obtained with the
DEL assay show high correlation with the carcino-
genicity ofthe test agents, the DEL assay could be use-
ful as ashort-term test forpredictive carcinogenesis.
This work has been carried out in part by funds from the
Department of Molecular and Cellular Toxicology, Harvard
University and by Grant No. R81-9477 from the Environmental
Protection Agency's Office ofExploratory Research.
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